Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis - The ADAMO Trial
Conditions: Low Bone Mass; Low Bone Mineral Density; Males With Osteoporosis; Osteopenia; Osteoporosis Interventions: Drug: 60 mg denosumab; Other: Placebo Sponsor: Amgen Active, not recruiting - verified August 2011